EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel CAF‐Related Signature for Precise Prediction of Clinical Outcomes and Immunotherapy Response for Breast Cancer Patients: Based on Multiomics Analyses and Experimental Validation

Qi Wang iD, Jing Chen, Shuyao Zhang, Yi Liu, Lian Xu, Lin Tian, Junqi Ren iD, Zhanhai Su iD, Zhengang Tang iD

Mediators of Inflammation · 2026-01 · 2026 (1)

DOI: 10.1155/mi/9934495 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mediators of Inflammation, online erschienen am 26.06.2026. Verfasst von Qi Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China, hbmu.edu.cn. Hauptthemen laut MEDLINE: Breast Neoplasms, Immunotherapy, Cancer-Associated Fibroblasts. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research Project of Graduate Education at Hubei University of Medicine, Shiyan City Guiding Research Project, Research Projects of Shiyan People's Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Breast cancer (BC) remains a leading cause of cancer‐related mortality worldwide. Cancer‐associated fibroblasts (CAFs) is a central stromal component of the tumor microenvironment (TME), critically influence BC progression and therapeutic resistance. However, the association between CAF heterogeneity and patient prognosis or response to immunotherapy remains poorly characterized. Here, we aimed to develop a CAF‐associated gene signature by integrating single‐cell RNA sequencing (scRNA‐seq) and bulk RNA‐seq data to predict clinical outcomes and immunotherapeutic response in BC.

Methods

Gene expression profiles and clinical data from BC patients were sourced from TCGA and GEO databases. scRNA‐seq data preprocessed (quality control, PCA, UMAP using Seurat) identified CAF‐related genes. Prognostic genes were identified via univariate Cox, lasso, and multivariate Cox regression. Single‐cell Gene Set Enrichment Analysis (scGSEA) assessed the signature’s link to immune infiltration and immunotherapy genes. R tools evaluated signature characteristics and real‐world applications. GO enrichment analysis was used to explore signaling pathways. CAF factor expression and CD8 + T‐cell correlation in clinical BC samples were validated using qPCR, immunohistochemical (IHC), multiplex immunofluorescence (mIF), and Western blot. Results scRNA‐seq analysis identified multiple CAF‐specific marker genes that formed the core of our signature. Eight genes (ANXA5, APOD, CXCL14, GSN, IGFBP4, PPIB, TCF7L2, and TMEM98) were associated with favorable prognosis (low‐risk), whereas three genes (SDC1, EMP1, and FAM114A1) conferred higher risk. A risk score model based on these 11 genes independently predicted overall survival (OS) across diverse BC pathological subtypes, demonstrating robust prognostic accuracy. Immune infiltration analysis revealed significantly reduced immune cell abundance in the high‐risk group compared to the low‐risk group, suggesting diminished responsiveness to immunotherapy. In tumor tissues relative to adjacent nontumor tissues, mRNA and protein levels of the high‐risk genes (SDC1, EMP1, and FAM114A1) were consistently elevated (all p < 0.05). Moreover, both Western blotting and mIF showed significantly higher CAF abundance in high‐risk samples ( p < 0.01), concomitant with markedly lower CD8 + tumor‐infiltrating lymphocyte counts ( p < 0.05). GO enrichment analyses indicated that CAFs promote BC evolution and progression through complex signaling networks. Key pathways included extracellular matrix (ECM) remodeling, cell adhesion, tumor associated inflammation, and oncogenic cascades such as KRAS, WNT, IL‐6/STAT3, and TNFα/NF‐κB highlighting CAFs as pivotal regulators and potential therapeutic targets in BC.

Conclusion

We present a novel CAF associated gene signature that robustly predicts prognosis and immunotherapy response in BC. As an independent prognostic indicator strongly correlated with immune infiltration, this model holds promise for guiding personalized therapeutic strategies. Future validation in large, multicenter cohorts and extension to other malignancies are warranted to facilitate clinical translation of CAF targeted biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsImmunotherapyCancer-Associated FibroblastsHumansFemaleTumor MicroenvironmentMultiomicsGene Expression Regulation, NeoplasticPrognosis

Stichwörter der Autor:innen

CD8+ t cell infiltrationbreast cancercancer-associated fibroblastssingle-cell RNA sequencingtumor microenvironment

Autor:innen und Institutionen

  • Department of Pathology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China, hbmu.edu.cn.
  • Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, Hubei, China, hbmu.edu.cn.
  • The Third Clinical College, Hubei University of Medicine, Shiyan, Hubei, China, hbmu.edu.cn.
  • Research Center for High Altitude Medicine, Qinghai University, Xining, Qinghai, China, qhu.edu.cn.
  • Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China, dlmedu.edu.cn.
  • Department of Pathology, The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China, gdmu.edu.cn.

ORCID-Profile: Qi Wang, Junqi Ren, Zhanhai Su, Zhengang Tang

Förderung

  • Key Research Project of Graduate Education at Hubei University of Medicine
  • Shiyan City Guiding Research Project
  • Research Projects of Shiyan People's Hospital
  • Hubei Key Laboratory of Wudang Local Chinese Medicine Research
  • Hubei University of Medicine
  • Joint Fund Project of Hubei Natural Science Foundation

Zitieren

APA

Wang, Q., Chen, J., Zhang, S., Liu, Y., Xu, L., Tian, L., Ren, J., Su, Z., & Tang, Z. (2026). A Novel CAF‐Related Signature for Precise Prediction of Clinical Outcomes and Immunotherapy Response for Breast Cancer Patients: Based on Multiomics Analyses and Experimental Validation. Mediators of Inflammation, 2026(1). https://doi.org/10.1155/mi/9934495

Vancouver

Wang Q, Chen J, Zhang S, Liu Y, Xu L, Tian L, et al. A Novel CAF‐Related Signature for Precise Prediction of Clinical Outcomes and Immunotherapy Response for Breast Cancer Patients: Based on Multiomics Analyses and Experimental Validation. Mediators of Inflammation. 2026;2026(1). doi:10.1155/mi/9934495

BibTeX
@article{Wang2026,
  author = {Wang, Qi and Chen, Jing and Zhang, Shuyao and Liu, Yi and Xu, Lian and Tian, Lin and Ren, Junqi and Su, Zhanhai and Tang, Zhengang},
  title = {A Novel CAF‐Related Signature for Precise Prediction of Clinical Outcomes and Immunotherapy Response for Breast Cancer Patients: Based on Multiomics Analyses and Experimental Validation},
  journal = {Mediators of Inflammation},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/mi/9934495}
}
Kostenlos starten →